We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Morgan Goodwin is a UK-based company that pioneers the Combined Trading Platform (CTP) category, offering a comprehensive online platform for small businesses engaged in physical goods trading, along with specialized software development services, and a broad-spectrum business consultancy approach aimed at enhancing growth, efficiency, and technological advancement.
days to go: Stretch investment: £788,519
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Doqit offers a solution for managing life admin tasks, helping you organize important information, set action dates, and receive timely reminders, ultimately streamlining tasks like insurance renewals and warranties to reduce unnecessary expenses and simplify your life. It provides secure storage and easy access for vital information, transitioning from chaos to simplicity.  Security is also a priority for Doqit. The platform ensures that your sensitive information is stored securely, giving you peace of mind knowing that you can access your important documents and data whenever you need them, all within a few clicks.
days to go: Extended investment: £87,500
UTU is a company dedicated to building the trust infrastructure for the evolving web 3.0. They aim to facilitate safer and more reliable interactions between users and platforms by utilizing a decentralized reputation and reviews protocol. This protocol involves a non-tradable reputation token (UTT) that users can stake to endorse others, leading to positive outcomes. UTU's focus initially lies in Web3 and DeFi apps, where they provide AI-powered tools to curate trust signals and help users engage confidently in various online activities. They offer a range of products, including the UTU Trust Token, Browser Extension, and Trust API/SDK, all aimed at enhancing trust and security in digital interactions.
days to go: Extended investment: £150,000
Medic Bleep is a simple, secure and innovative patient-focused solution to communication challenges that healthcare professionals and the wider team in the UK National Health Service (NHS) face while going about their everyday work. It is saving each nurse & each junior doctor an estimated 48 minutes per shift. This coincides with the UK's Department of Health calling for a ban on pagers. If implemented across the NHS, it could free up the time to care for an estimated 11,000 nurses. To ensure data privacy and safety, the company allows communication to occur via the app. As a result of these safeguards and its user-friendly portal, the company's app has been downloaded 16,000 times by UK doctors and nurses. With the funds raised, the company will aim to solve looming technology gaps for over 30% of the NHS in the next 3 years and expand globally.

Pitch Rated

83%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £814,600
CatchApp is a scheduling software that aims to fulfil the scheduling needs of Small and Medium Enterprises (SMEs), professionals, and enterprise users. CatchApp has 15,000 users using its application. It has featured in the US 'Appstore's' home screen and selected by Apple as 'App of the Day'. CatchApp is used by organisations like Microsoft, CERN, PwC, Harvard, and NHS. Calendars from Google, Apple, and Microsoft Outlook are compatible with the software. The business productivity software market will grow from $98 billion in 2018 to $106 billion in 2021, and CatchApp aims to be a major contender in this segment. The company will use the investment to build up marketing, business development and technical teams, accelerate revenue from SMEs via the company’s newly-launched Software as a Service (SaaS) product, launch CatchApp Enterprise solutions, and global partnerships.

Pitch Rated

80%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £832,102
Glug provides a platform for businesses to let customers order from a digital menu and have them served to the table or pick up from the bar. It points out that its system is designed to be user friendly and easy to set up wherein restaurants or bars can upload and digitalise their menu and can be discoverable within 24 hours. Consumers can discover the restaurant, book a table, place an order, and browse for offers and discounts, amongst other features using the company's community app. Glug asserts that more than 16,000 users have ordered food and drinks through its app in less than four months since the company's launch. It intends to become a contender in the UK dining and pub market that is a £40 billion+ industry. Glug argues that more than 20,000 users have downloaded its app from the App Store and Google Playstore. It will use the investment for marketing, hiring, technology development, attract 1.5 million users and onboard 1,000+ venues over the next 12 months.

Pitch Rated

71%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £73,114
StepJockey are aiming to create healthier, more active buildings by labeling the stairs of the world for calorie burn. StepJockey are encouraging people to take the stairs as opposed to the elevator.
days to go: Expired investment: £280,370
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph